Lercanidipine With EnalaprilZan-Extra
Recommended CardiovascularRestricted
Hypertension in patients who are not adequately controlled with either lercanidipine or enalapril monotherapy.
1
Submissions
2008–08
On the record
—
ICER range
Cost-min
Cost basis
Decision on record
- Meeting Mar 2008 Recommended High blood pressure
Access path
- TGA registered · Zan-Extra
TGA label narrower than the PBS population
- Mar 2008Recommended · restricted
vs lercanidipine and enalapril monotherapy
- PBS listing · Restricted
RecommendedDeferredNot recommended
Cost-effectiveness
Cost-minimisation analysis; no ICER calculated by design.
The submission presented a cost minimisation analysis. PSD · 2008
Decision context
PopulationAdults with mild to moderate essential hypertension not adequately controlled with either lercanidipine or enalapril monotherapy.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2008 | Recommended · restricted | lercanidipine and enalapril monotherapy | — | RCT · Other |
Similar precedents
Ramipril With Felodipine75%Amlodipine Besylate With Valsartan73%Olmesartan Medoxomil With Amlodipine71%Valsartan With Hydrochlorothiazide71%Perindopril Arginine With Amlodipine Besylate70%Olmesartan Medoxomil With Hydrochlorothiazide70%Trandolapril With Verapamil Hydrochloride-Sr69%Amlodipine (As Besylate) With Valsartan And Hydrochlorothiazide69%
Regulatory · TGA
Label narrower than PBS population — PBAC restricts to patients inadequately controlled on lercanidipine or enalapril monotherapy; TGA label permits any hypertension.